Thelansis

  Follicular lymphoma (FL), commonly referred to as indolent lymphoma, is the second most common type of non-Hodgkin lymphoma (NHL). After treatment, many FL patients fail to respond, and these tumors are categorized as refractory lymphomas. Some react with an initial positive change but then develop signs of recurrent tumor, called relapsed follicular lymphoma. Advanced stage disease is considered incurable and is characterized by a prolonged relapsing/remitting course. A significant minority have less favorable outcomes, particularly those with transformed or early progressive disease. The introduction of anti-CD20 monoclonal antibodies (mAb) such as rituximab and, more recently, type II anti-CD20 mAb, obinutuzumab, has revolutionized the management of FL, and anti-CD20 antibodies will likely remain at the forefront of the FL treatment armamentarium. But more recent insights demonstrating the intricate relationship between the FL tumor cell and its distinct immune microenvironmen...